McDermott Will & Schulte wins significant patent trial against Liquidia over YUTREPIA® PH-ILD treatment
McDermott Will & Schulte won a patent trial for United Therapeutics (UTC) against Liquidia, with a court ruling that Liquidia infringed on UTC's patent for PH-ILD treatment. The decision may impact Liquidia's ability to market YUTREPIA®. UTC has previously won similar cases against Liquidia.
How this was made
The 30-second read
Why it matters
The decision removes a major barrier to United Therapeutics' market exclusivity for its PH‑ILD therapy, likely supporting revenue outlook.
Market read
The ruling is a primary corporate event that can influence United Therapeutics' stock price and biotech IP risk perception.
What to watch
Potential market reaction may be muted if investors had already priced in the litigation outcome.
Background
United Therapeutics has been litigating Liquidia over the ’327 patent covering treprostinil treatment for PH‑ILD. The recent trial opinion affirms infringement and invalidity challenges.
Ticker impact
United Therapeutics (UTHR) won a patent trial against Liquidia, preserving its ability to block YUTREPIA® sales.
upward pressure as investors price in reduced litigation risk
A fresh court decision favoring UTHR is a material, first‑report event that can move the stock immediately.
Market effects
Strengthens confidence in biotech patent enforcement, may benefit peers facing similar IP disputes.
Limited to U.S. biotech sector; no broader regional effect.
Minimal global impact beyond investors tracking United Therapeutics.
Counterpoint
If Liquidia appeals successfully, the win could be short‑lived and the stock may face renewed downside.
Key entities
- CompanyUnited Therapeutics Corporation
US biotech firm holding the ’327 patent.
- CompanyLiquidia Technologies, Inc.
Biotech company accused of infringing the patent.
